Immunomodulating effects of the single bacterial strain therapy EDP1815 on innate and adaptive immune challenge responses - a randomized, placebo-controlled clinical trial.

Immunol Res · 2024 · PMC11347467 · PMID 38748319

Europe PMC DOI

hedged sentence

0.0520

closest p · 1.0× alpha

0.0520

boldest claim

The sentences

borderline significantp = 0.052so close (0.05 < p ≤ 0.1)

For EC1 compared to placebo, but not for EC2, the reduction in inflammatory cells was also significant in case of total cells (EC1, p = 0.046; EC2, p = 0.435; overall p = 0.128) and NK-cells (EC1, p = 0.046; EC2, p = 0.190; overall p = 0.128), and borderline significant for T cells (EC1, p = 0.052; EC2, p = 0.703; overall p = 0.117).

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.